Sword Health vs Cardinal Health
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI digital physical therapy platform. $4B valuation. $240M ARR, cash-flow positive. 2,500+ employers. Founded 2015, Porto/NYC. Raised $340M+. Private.
About
Sword Health is a digital musculoskeletal care company founded in 2015 and headquartered in New York City with engineering roots in Porto, Portugal. The company was founded by physical therapist and engineer Virgílio Bento with the mission of freeing two billion people from pain using AI-powered physical therapy that matches or exceeds the clinical outcomes of in-person care. Sword pioneered the use of sensor-equipped motion trackers combined with AI therapy guidance delivered through a tablet interface.\n\nSword's platform pairs each member with a licensed physical therapist who designs and supervises a personalized program, while an AI engine called Phoenix handles real-time biomechanical coaching during sessions, monitors adherence, and flags clinical concerns for human review. Programs cover the full MSK spectrum — back, neck, shoulder, hip, knee, and post-surgical rehabilitation — as well as pelvic health through its Bloom product. Sword sells to self-insured employers and health plans; it has contracted with more than 2,500 enterprise customers including major Fortune 500 companies.\n\nSword reached $240 million in annualized recurring revenue and achieved cash-flow positivity, a rare milestone among digital health companies at its stage. The company has raised more than $340 million in total funding, reaching a $4 billion valuation. Its clinical evidence base — spanning dozens of peer-reviewed studies demonstrating meaningful pain reduction and return-to-work rates — differentiates Sword in a crowded MSK market and supports its position as the leading AI-native physical therapy platform.
Dublin OH pharmaceutical distribution (NYSE: CAH) $230B+ revenue; specialty pharma GLP-1 distribution tailwind, at-Home Solutions growth, medical divestiture to Medline competing with McKesson and Cencora.
About
Cardinal Health, Inc. is a Dublin, Ohio-based healthcare distribution and medical products company — publicly traded on the New York Stock Exchange (NYSE: CAH) as an S&P 500 Health Care component — distributing pharmaceutical products to pharmacies, hospitals, and healthcare providers, and manufacturing and distributing medical and surgical supplies through approximately 44,000 employees. In fiscal year 2025 (ending June 2025), Cardinal Health generated revenues exceeding $230 billion in its Pharmaceutical and Specialty Solutions segment — reflecting the company's role as a pass-through distributor of branded and generic pharmaceuticals at near-zero margin on drug cost, where Cardinal Health earns distribution fees and rebate income on enormous volumes. CEO Jason Hollar has executed a two-segment strategy focused on optimizing pharmaceutical distribution (Pharmaceutical and Specialty Solutions — $227B+ revenue at low margin) and growing medical products profitability (Global Medical Products and Distribution — higher-margin branded surgical products, Cardinal Health brand commodities, and at-Home Solutions). The 2024 divestiture of the medical segment's Cardinal Health Brand product line to Medline Industries for $1.1 billion simplified the medical segment focus toward specialty distribution and home healthcare supply. Cardinal Health's specialty pharmaceutical distribution (oncology, rheumatology, rare disease biologics through Cardinal Health Specialty Solutions) is a growing higher-margin subsegment as pharmaceutical manufacturers contract with specialty distributors for controlled dispensing of limited-distribution drugs.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.